Burnham Institute
Member
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040344
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Ian M. Rosenthal1,2, Ming Zhang1, Kathy N. Williams1, Charles A. Peloquin3, Sandeep Tyagi1, Andrew A. Vernon4, William R. Bishai1,2, Richard E. Chaisson1,2, Jacques H. Grosset1, Eric L. Nuermberger1,2*
1 Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 3 Infectious Diseases Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, Colorado, United States of America, 4 Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Conclusions
Rifapentine should no longer be viewed solely as a rifamycin for once-weekly administration. Our results suggest that treatment regimens based on daily and thrice-weekly administration of rifapentine and moxifloxacin may permit shortening the current 6 mo duration of treatment to 3 mo or less. Such regimens warrant urgent clinical investigation.
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Ian M. Rosenthal1,2, Ming Zhang1, Kathy N. Williams1, Charles A. Peloquin3, Sandeep Tyagi1, Andrew A. Vernon4, William R. Bishai1,2, Richard E. Chaisson1,2, Jacques H. Grosset1, Eric L. Nuermberger1,2*
1 Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 3 Infectious Diseases Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, Colorado, United States of America, 4 Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Conclusions
Rifapentine should no longer be viewed solely as a rifamycin for once-weekly administration. Our results suggest that treatment regimens based on daily and thrice-weekly administration of rifapentine and moxifloxacin may permit shortening the current 6 mo duration of treatment to 3 mo or less. Such regimens warrant urgent clinical investigation.